semaglutide news november 2025 ESC 2025: Novo Nordisk's Wegovy superior to Zepbound in reducing CV events Trump administration gets lower prices

Yet striking first does not always presage market dominance

Here is the breakdown by dose group from the trial: 4 mg dose group: average weight loss of 8.7% 8 mg dose group: average weight loss of 17.3% 12 mg dose group: average weight loss of 24.2% Placebo group: average weight loss of 2.1% The 12 mg group also showed that 26% of participants lost 30% or more of their body weight

Semaglutide is a long-acting glucagon-like peptide 1 (GLP-1) agonist, while tirzepatide is both a GLP-1 agonist and a glucose dependent insulinotropic polypeptide (GIP)

her weight loss had hit a plateau and she wanted to find a solution once and for all